GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News:
The United States Patent and Trademark Office (USPTO) today issued a patent related to Astepro (azelastine) nasal spray. This patent will be listed in the FDA’s Approved Drug Products List (the Orange Book). The Astepro patent is valid until 2028.